Key takeaways

  • The first approved PROTAC, Arvinas and Pfizer's Veppanu (vepdegestrant), won FDA approval on May 1, 2026. Rights now sit with Rigel, and Arvinas booked only $0.5 million in royalties in Q3 2026.
  • Asian degraders are closest to the next approval: BeOne's BTK degrader tacabrutideg met the primary endpoint of its pivotal Phase 2 with a filing planned for mid-2027, and Astellas has started a 614-patient Phase 3 of its KRAS G12D degrader setidegrasib in pancreatic cancer.
  • Taiwan is taking a topical route: AnHorn Medicines completed a 64-subject Phase 1 of AH-001, a topical androgen receptor (AR) degrader for androgenetic alopecia. Its closest rival is Kintor's GT20029, which finished a 180-patient Phase 2 in China.

Key numbers (with sources)

ItemValueDateSource
Veppanu (vepdegestrant) FDA approval2026-05-012026-05-01https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast
VERITAC-2 median PFS, ESR1-mutant (Veppanu vs fulvestrant)5.0 vs 2.1 months2026-05-01Same
VERITAC-2 objective response rate19% vs 4%2026-05-01Same
Arvinas Q3 2026 revenue (all Rigel royalties)$0.5 million2026-11-03https://www.sec.gov/Archives/edgar/data/0001655759/000162828026069101/q32026earningsrelease.htm
Arvinas Q3 2025 revenue$41.9 million2026-11-03Same
Astellas setidegrasib Phase 3 planned enrollment (NCT07409272)6142026-11-03https://clinicaltrials.gov/study/NCT07409272
BeOne tacabrutideg planned filing after pivotal Phase 2 (CaDAnCe-101) met its primary endpointMid-20272026-11-05https://www.biospace.com/press-releases/beone-medicines-announces-third-quarter-2026-financial-results-and-business-updates
BeOne tacabrutideg Phase 3 planned enrollment (NCT06846671)2502026-09-28https://clinicaltrials.gov/study/NCT06846671
AnHorn AH-001 Phase 1 actual enrollment (NCT06927960)642025-12-19https://clinicaltrials.gov/study/NCT06927960
Kintor GT20029 China Phase 2 actual enrollment (NCT06692465)1802024-11-18https://clinicaltrials.gov/study/NCT06692465

On November 5, BeOne said its BTK degrader tacabrutideg met a pivotal Phase 2 goal.

A filing is planned for mid-2027.

Two days earlier, Arvinas reported third-quarter results.

The company built the world's first approved PROTAC, yet the quarter brought in just $0.5 million.

A year earlier the same quarter showed $41.9 million, mostly Pfizer collaboration revenue.

That revenue has run off, the drug's rights now belong to Rigel, and what remains is a royalty stream.

BeOne is not alone in Asia.

Astellas has a KRAS G12D degrader in a pancreatic cancer Phase 3, and BeOne's degrader is also in a Phase 3 race against Nurix.

The first leg is done. The second leg is being run in Asia.

01 | Degraders don't block a protein, they throw it away

A conventional targeted drug works like a key jammed into a lock: it blocks the disease protein's active site.

The protein stays, and once a mutation changes the lock, the drug stops working.

A degrader grabs the disease protein with one end and an E3 ligase, the cell's recycling tag, with the other.

The protein is marked for disposal and destroyed by the proteasome.

Because the whole protein disappears, resistance mutations go with it.

That is the core case for degraders: treating patients whose targeted drugs have stopped working.

Figure 1 | How a degrader sends a disease protein to the cell's recycling bin

Source: Drugnews synthesis (2026-11-10)

02 | Lesson from the first approval: degradation alone doesn't make a blockbuster

In VERITAC-2, Veppanu beat fulvestrant in ESR1-mutant breast cancer: median progression-free survival of 5.0 versus 2.1 months and a response rate of 19% versus 4%.

But the label covers only ESR1-mutant patients after at least one line of endocrine therapy, a narrow market where oral SERDs already compete.

Whether a degrader becomes a big drug depends on the target and the patients, not on how new the technology is.

Arvinas handed the rights to Rigel and is redirecting resources to BCL6, HPK1 and LRRK2.

Its BCL6 degrader ARV-393 will present first monotherapy data at ASH on December 12–15.

03 | Asia's two Phase 3 bets both target places where inhibitors fail

BeOne tacabrutideg: the next line after BTK inhibitors. The Phase 3 enrolls chronic lymphocytic leukemia patients previously exposed to both BTK and BCL2 inhibitors, about 250 patients, against investigator's choice.

On November 5 BeOne added another piece: the pivotal Phase 2 portion of CaDAnCe-101 met its primary endpoint of overall response rate.

Six tacabrutideg abstracts were accepted for the ASH meeting in December.

This is home turf for degraders.

Long-term BTK inhibitor use breeds resistance mutations; a degrader removes the whole BTK protein regardless of mutation.

Nurix's bexobrutideg is in Phase 3 on the same target, so whichever reads out first will define the new class.

Nurix said on November 5 it will present updated Phase 1 bexobrutideg data at ASH on December 13.

Astellas setidegrasib: KRAS G12D, with no approved targeted drug. KRAS mutations drive most pancreatic cancers and G12D is the most common, yet no G12D-targeted drug is approved. Astellas is testing setidegrasib with mFOLFIRINOX or NALIRIFOX against placebo in about 614 patients, enrolling since February 17, 2026.

Figure 2 | Asian and global degraders on one scale

Source: ClinicalTrials.gov (2026-11-03)

CompanyDrugTargetHighest registered stageOrigin
BeOnetacabrutideg (BGB-16673)BTKPhase 3, recruitingChina-founded
Astellassetidegrasib (ASP3082)KRAS G12DPhase 3, recruitingJapan
Nurixbexobrutideg (NX-5948)BTKPhase 3, recruitingUS
BMSBMS-986365ARPhase 3US
KintorGT20029 (topical)ARPhase 2, completedChina
HinovaHP518ARPhase 1/2, recruitingChina
HengruiHRS-1358ERPhase 1/2, recruitingChina
Ubix TherapeuticsUBX-303061BTKPhase 1, recruitingSouth Korea
AnHorn MedicinesAH-001 (topical)ARPhase 1, completedTaiwan

China has the densest pipeline: Hengrui has both AR and ER degraders, Hinova and Qilu each have an AR degrader, Haisco works on BTK and mutant EGFR, and InnoCare pursues a molecular glue.

South Korea's Ubix joins BeOne and Nurix on BTK. Not every bet works: BeOne's IRAK4 degrader BGB-45035 shows a terminated Phase 2.

Figure 3 | How far degraders have advanced, by country

Source: ClinicalTrials.gov (2026-11-03)

04 | Taiwan: AnHorn goes topical, away from systemic oncology

AnHorn's AH-001 is an AR degrader applied to the scalp for androgenetic alopecia.

Oral anti-androgens act body-wide; a topical degrader is designed to clear AR in the scalp.

Its Phase 1 began in March 2025, enrolled 64 subjects in single and multiple ascending doses, and is registered as completed.

The closest comparator is Kintor's topical GT20029, whose China Phase 2 in 180 adult men was completed on June 30, 2024.

For Taiwan, the test is whether AnHorn's Phase 2 hair data can beat GT20029. Hair loss is a self-pay, long-term market with a very different economics from a narrow oncology label.

Figure 4 | Topical AR degraders: AnHorn vs Kintor

Source: ClinicalTrials.gov (2025-12-19, 2024-11-18)

05 | Three things to watch

The first approval proved degraders can be made into medicines, and that technology alone does not sell.

Three milestones will reshape the field: ARV-393 BCL6 data at ASH in December; BeOne's mid-2027 filing and which BTK Phase 3, BeOne or Nurix, reads out first; and the start and design of AnHorn's AH-001 Phase 2.

If either Asian Phase 3 succeeds, the second approved degrader may well come from Asia.

This article is industry and company analysis and is not investment or medical advice.

References

Share this analysis

Send this article to readers who follow biotech, company strategy, and capital-market signals.

Cite this article

For decks, research notes, or media references, cite Drugnews with the canonical article URL.

Drugnews Editorial Team. "Asia's Protein Degraders After First PROTAC." Drugnews, Nov 10, 2026. https://drugnews.com.tw/articles/2026-11-10-asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn-en.html
This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.

Read this next

Continue with the most relevant Drugnews analysis on the same theme.

Nov 06, 2026Business Analysis

The Semiconductor Moment in AI Drug Discovery

How AI platforms and the discovery flywheel could open new partnership opportunities for AnHorn

AI
Nov 07, 2026Business Analysis

Rasonque Sold $198M in Five Weeks, 7x Above Forecast

Rasonque booked $197.6M in about five weeks and reached 5,000+ U.S. patients. Second-line chemo goes first; next comes first line and RAS-plus-PRMT5 combos, a mixed picture for Taiwan's PharmaEngine.

pancreatic cancerRasonqueRAS inhibitorsPharmaEnginePRMT5
Jul 25, 2026Business Analysis

Roche's Hidden Succession Engine: How 19 New Molecules Could Power the Next Growth Cycle

Roche generated CHF 47.669 billion in pharmaceutical sales in 2025, with Ocrevus, Hemlibra, and Vabysmo already accounting for roughly one-third of the total. The number that matters is not simply 19 potential new molecules, but whether giredestrant, fenebrutinib, obesity, Alzheimer's, and protein-degradation assets can inherit Roche's existing clinical, diagnostic, and commercial infrastructure on time.

RocheBig Pharmapharma strategygiredestrantfenebrutinib